$RGNT

Regentis Biomaterials (RGNT) reported strong interest in GelrinC, its CE Mark-approved knee cartilage repair implant, at the ICRS Summit. The company highlighted GelrinC's clinical results, ease of use, and potential to address a significant unmet need. Regentis is focused on expanding clinical adoption in Europe and advancing its U.S. FDA pivotal trial.

Regentis Biomaterials (RGNT) is developing GelrinC, a hydrogel implant for knee cartilage repair. Phase II data showed 100% greater improvement than microfracture at two years. GelrinC has CE Mark approval in Europe, with U.S. trial completion targeted for late 2026. The company aims to position itself as a key player in the evolving cartilage repair market, potentially delaying or preventing knee replacements.

Regentis Biomaterials (RGNT) is developing GelrinC, a treatment for knee cartilage repair. The product has early clinical support and European approval, with a U.S. trial ongoing. Researchers at Duke University and Mayo Clinic are also exploring cartilage regeneration. GelrinC aims to support natural cartilage repair, addressing a challenging medical issue.

Regentis Biomaterials (NYSE American:RGNT) reported H1 2026 results, highlighting progress in GelrinC U.S. trial with 43 patients treated and enrollment expected to complete by year-end. The company expanded European commercialization efforts and improved production yield by 400%. Regentis raised $6.5M in a private placement, with cash reserves of $9M as of June 30, 2026. H1 2026 net loss was $2.6M, an improvement from the same period in 2025.

REGENTIS BIOMATERIALS LTD. (RGNT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026 Expands European commercialization readiness,

Regentis Biomaterials (NYSE American: RGNT) priced a $6.5 million private placement with accredited and institutional investors at $3.50 per ordinary share, plus accompanying warrants (or $3.4999 per pre-funded warrant). The company will issue 1,857,143 shares (or pre-funded warrants) and warrants to buy 1,857,143 shares. Pre-funded warrants are exercisable at $0.0001; ordinary warrants at $4.20 for five years. Net proceeds will fund its GelrinC pivotal trial, FDA pre-market approval preparation

Regentis Biomaterials (NYSE: RGNT) shares moved sharply after the company filed a Form 6-K with the SEC, saying it requested withdrawal of its Form F-1 registration statement and decided not to pursue the related public offering. The stock rose 506.45% to $9.40 intraday, then fell 9.15% to $8.54 in after-hours.

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

Regentis Biomaterials (NYSE: RGNT) has filed an F-1 registration statement to sell 3,333,334 Ordinary Shares at an assumed public offering price of $3.00 per share. The company is developing GelrinC, a regenerative medicine product for articular knee cartilage repair, which is currently undergoing a pivotal clinical trial. Regentis aims to use the net proceeds from this offering for further clinical development of GelrinC, research and development activities, operational readiness, and European market entry.